Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBITDA (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of EBITDA data on record, last reported at -$27.0 million in Q3 2025.

  • For Q3 2025, EBITDA fell 14.65% year-over-year to -$27.0 million; the TTM value through Sep 2025 reached $20.0 million, up 116.65%, while the annual FY2024 figure was -$73.3 million, 46.21% up from the prior year.
  • EBITDA reached -$27.0 million in Q3 2025 per GLUE's latest filing, down from -$12.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $46.9 million in Q1 2025 and bottomed at -$35.4 million in Q2 2023.
  • Average EBITDA over 3 years is -$18.4 million, with a median of -$30.3 million recorded in 2024.
  • The widest YoY moves for EBITDA: up 246.89% in 2025, down 14.65% in 2025.
  • A 3-year view of EBITDA shows it stood at -$34.5 million in 2023, then soared by 135.93% to $12.4 million in 2024, then crashed by 317.33% to -$27.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$27.0 million in Q3 2025, -$12.3 million in Q2 2025, and $46.9 million in Q1 2025.